Benmelstobart plus anlotinib versus pembrolizumab as first-line treatment for PD-L1-positive, advanced non-small-cell lung cancer (CAMPASS): a blinded, randomised, controlled, phase 3 trial

Journal:
The Lancet Oncology
Published:
DOI:
10.1016/s1470-2045(26)00049-5
Affiliations:
21
Authors:
26
Go to article
Institutions Authors Share
Shanghai Chest Hospital, SJTU, China
5.000000
 0.19
Tianjin Medical University Cancer Institute and Hospital, TMU, China
2.000000
 0.08
Cangzhou People's Hospital, China
2.000000
 0.08
Cancer Hospital of Yunnan Province, China
1.000000
 0.04
Hunan Cancer Hospital, China
1.000000
 0.04
The First Affiliated Hospital of Nanchang University, China
1.000000
 0.04
Shandong Cancer Hospital, China
1.000000
 0.04
Affiliated Hospital of Chengde Medical University, China
1.000000
 0.04
Shenyang Chest Hospital, China
1.000000
 0.04
Northern Jiangsu People's Hospital, China
1.000000
 0.04
Harbin Medical University Cancer Hospital, China
1.000000
 0.04
Hainan General Hospital, China
1.000000
 0.04
Xiangyang Central Hospital, China
1.000000
 0.04
Anhui Chest Hospital, China
1.000000
 0.04
Jiamusi Tumor Hospital, China
1.000000
 0.04
Affiliated Hospital of Guangdong Medical University, GDMU, China
1.000000
 0.04
The First Affiliated Hospital of Gannan Medical University, China
1.000000
 0.04
Affiliated Hospital, IMMU, China
1.000000
 0.04
Linyi Cancer Hospital, China
1.000000
 0.04
Henan Cancer Hospital, ZZU, China
0.500000
 0.02
Henan Academy of Innovations in Medical Science, China
0.500000
 0.02
Interested in Oncology and Carcinogenesis?